@entity19316 Produces Antidepressant-Like Effects in @entity19 Through Promotion of XXXX Signaling Pathway.

@entity9140 @entity308 @entity19316 @entity6635 @entity19 @entity8312 @entity1062
BACKGROUND: Current antidepressants are clinically effective only after several weeks of administration. @entity19316 ( @entity8312 ) is an identified component of Ligusticum wallichii with neuroprotective effects. Here, we investigated the antidepressant effects of @entity8312 in @entity19 models of @entity308 . METHODS: Antidepressant effects of @entity8312 were first detected in the forced swim test (FST) and @entity1062 ( @entity1062 ), and further assessed in the chronic social defeat stress (CSDS) model. Changes in the @entity9140 ( @entity9140 ) signaling pathway and in hippocampal neurogenesis after CSDS and @entity8312 treatment were then investigated. A @entity6635 hydroxylase inhibitor and @entity9140 signaling inhibitors were also used to determine the mechanisms of @entity8312 . RESULTS: @entity8312 exhibited potent antidepressant effects in the FST and @entity1062 without affecting locomotor activity. @entity8312 also prevented the CSDS-induced symptoms. Moreover, @entity8312 completely restored the CSDS-induced decrease of @entity9140 signaling pathway and hippocampal neurogenesis. Furthermore, a blockade of the @entity9140 signaling pathway prevented the antidepressant effects of @entity8312 , while @entity8312 produced no influence on the monoaminergic system. CONCLUSIONS: In conclusion, these data provide the first evidence that @entity8312 has antidepressant effects, and this was mediated by promoting the @entity9140 signaling pathway.
